CD274 and myeloid leukemia: In this study, our original intention was to evaluate the therapeutic efficacy of the combined immunotherapeutic strategy of peptide-based DCs prime_TriVax booster regimen with PD-L1 blockade in orthotopically established myeloid leukaemia, which offer more clinically relevant tissue site-specific tumour setting.